# Stromedix

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/stromedix

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.stromedix.com
- Total disclosed funding: $30M
- Latest round: Series B (Mar 13, 2008)
- Investors on record: 5

## About

Founded in 2005 and is based in Cambridge, Massachusetts, Stromedix is a clinical-stage biotechnology company, develops drugs to treat fibrotic organ failure. It offers STX-100, a humanized monoclonal antibody that provides anti-fibrotic activity in preclinical models of lung, kidney, and liver diseases.

## Funding rounds

- Series B, Mar 13, 2008, $25M — Atlas Venture, Frazier Healthcare Partners, Red Abbey, New Leaf Venture Partners, Bessemer Venture Partners
- Series A, Jun 18, 2007, $4.4M — Atlas Venture
- Series A, Mar 8, 2007, $1M — Atlas Venture, Frazier Healthcare Partners

## Investors

- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Series A, Series B
- Frazier Healthcare Partners (https://capitalatlas.ai/funds/frazier-healthcare-partners) — Series A, Series B
- Red Abbey (https://capitalatlas.ai/funds/red-abbey) — Series B
- New Leaf Venture Partners (https://capitalatlas.ai/funds/new-leaf-venture-partners) — Series B
- Bessemer Venture Partners (https://capitalatlas.ai/funds/bessemer-venture-partners) — Series B